Showing 1 - 2 results of 2 for search 'Matthias E Schwenkglenks', query time: 0.01s Refine Results
  1. 1
    Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

    Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. by Tarun Mehra, Judith E Lupatsch, Thibaud Kössler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

    Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. by Tarun Mehra, Judith E Lupatsch, Thibaud Koessler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: